Key Opinion Leader. Dr. Harrison is a peer-reviewer for over 20 medical journals and internationally known for studies in hepatitis C and non-alcoholic fatty liver disease. He has over 150 peer reviewed publications in these fields and consults for many of the leading NASH pharmaceutical companies.
Why Investors Should Care:
Dr. Harrison is a leading expert on NASH including the development of guidelines and definitions.
The conversation will focus not just on GENFIT’s elafibranor, but the NASH landscape overall, including market size and patient identification. With the focus large pharmaceutical companies have placed on the disease in recent years, it is an area that is particularly interesting to healthcare investors.
The call will examine the nuances of the public data for elafibranor and give investors a deep dive into the drug’s potential.
Who's the Expert?
Retiring from the service in 2016, he spent 20 years in the United States Army. During that time he servd as the Director of Graduate Medical Education at Brooke Army Medical Center, Associate Dean for the San Antonio Uniformed Services Health Education Consortium & Gastroenterology Consultant to the Army Surgeon General
Consultant and Speaker for many leading Pharmaceutical companies including Alexion, Gilead, Allergan, Fibrogen, Genfit, Galmed, Intercept, Novartis, Pfizer and many more.
Peer-reviewer for over 20 medical journals and internationally known for studies in hepatitis C and non-alcoholic fatty liver disease. Dr. Harrison has over 150 peer reviewed publications in these fields..
Questions Investors Are Asking the Expert:
Please describe your background in NASH drug development and clinical practice.
Can you walk us through a typical NASH patient's journey to the extent that there is a 'typical'. How do they typically present, what are first and second line treatments? How successful are treatments to address NASH now and what other co-morbidities do they typically have?
How aggressively are patients diagnosed with NASH currently? Are a large number of patients identified?
At a high level how excited are you about NASH drugs that are in development, particularly in Phase 3 trials?
GENFIT, and subsequently other programs, are using the consensus definition of "NASH resolution" as endpoint. What is the relevance of this endpoint?
Focusing on Elafibranor's potential, what are your thoughts on the RESOLVE-IT trial and the Phase 2 results that have been publicly disclosed?
Can you walk us through the cardiometabolic risk benefits elafibranor has shown in the clinic, and how that differentiates from other programs out there?
When the FDA finally approves the first therapies for NASH, what sort of launch trajectory would you anticipate? What approved drugs in liver diseases or other diseases might be a good comp for us to look at?
Given that NASH is both a chronic and an asymptomatic condition, how does the safety and tolerability profile of the different programs position for monotherapy and combination therapies?
If you’re interested in accessing this call on the NASH landscape and adding your questions for the expert visit here for the Expert Interview Details!